2:28 PM
Feb 13, 2018
 |  BC Extra  |  Financial News

Catalyst prices $100M follow-on

Catalyst Biosciences Inc. (NASDAQ:CBIO) raised $100 million through the sale of 2.9 million shares at $34 in a follow-on underwritten by JonesTrading Institutional Services, Ladenburg Thalmann, LifeSci Capital and B. Riley FBR. The price is a 4% discount to the company’s close of $35.60 on Monday, when the offering was proposed after market hours.

In January, Catalyst began a Phase II/III trial of marzeptacog alpha to prevent bleeding in patients with hemophilia A or B with inhibitors. Interim data are expected this half. The product is a next-generation Factor VIIa variant.

Catalyst slipped $1.24 to $34.36 on Tuesday.

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD